MBX Biosciences (MBX) Net Cash Flow (2023 - 2026)
MBX Biosciences has reported Net Cash Flow over the past 4 years, most recently at -$29.9 million for Q1 2026.
- Quarterly results put Net Cash Flow at -$29.9 million for Q1 2026, down 53.59% from a year ago — trailing twelve months through Mar 2026 was $15.5 million (up 380.99% YoY), and the annual figure for FY2025 was $25.9 million, up 37.76%.
- Net Cash Flow reached -$29.9 million in Q1 2026 per MBX's latest filing, up from -$147.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $183.3 million in Q3 2025 and bottomed at -$147.8 million in Q4 2025.
- Median Net Cash Flow over the past 4 years was -$21.2 million (2024), compared with a mean of -$2.5 million.
- Peak annual rise in Net Cash Flow hit 143.09% in 2025, while the deepest fall reached 496.74% in 2025.
- Over 4 years, Net Cash Flow stood at -$40.1 million in 2023, then tumbled by 108.36% to -$83.5 million in 2024, then plummeted by 77.02% to -$147.8 million in 2025, then surged by 79.8% to -$29.9 million in 2026.
- Business Quant data shows Net Cash Flow for MBX at -$29.9 million in Q1 2026, -$147.8 million in Q4 2025, and $183.3 million in Q3 2025.